PLEASANTON, Calif., Dec. 23, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming 39th Annual J.P. Morgan Virtual Healthcare Conference.
Here is the original post:
10x Genomics to Present at the 39th Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia, Dec. 23, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today announces its intention to make an interim distribution to its registered shareholders in January 2021 (the “Interim Distribution”). The Interim Distribution will be made pursuant to an Order of the Supreme Court of British Columbia (the “Court”) dated December 16, 2020 in accordance with the Company’s Liquidation Plan. The mechanics of the Interim Distribution are in the process of being finalized and the date of the Interim Distribution will be communicated to the Company’s shareholders by way of a subsequent press release once confirmed.
See the original post here:
Novelion Announces Court Approval for Interim Distribution to Registered Shareholders
Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine Leading experts to evaluate the clinical and regulatory path to approval in the US market of COVAXIN™, a whole-virion inactivated COVID-19 vaccine
See the original post:
Ocugen Establishes Vaccine Scientific Advisory Board
PRESS RELEASE – REGULATED INFORMATION
See the original post here:
Bone Therapeutics SA: Transparency notification received from CPH Banque
BOGOTÁ, Colombia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Medcolcanna Organics Inc. (“Medcolcanna”, “MCCN” or the “Company”) (NEO: MCCN), a leading Colombian and globally integrated cannabis company, is pleased to announce that it has closed on the second and final tranche of its previously announced offering of convertible debentures as per the press release dated August 28, 2020, raising gross aggregate proceeds of $0.25 million, bringing the total amount raised pursuant to this offering to $1.25 million, being the full amount previously disclosed. The offering consists of convertible secured debentures (the “Debentures”). The Debentures are convertible into common shares in the capital of the Company (“Common Shares”) on the following terms: the Debentures are issuable in $1,000 increments and are convertible into Common Shares at a price of $0.20 per share (meaning 5,000 shares may be issued on the conversion of each Debenture) and will have a term of two (2) years from the date of issuance, with interest payable twice yearly of fourteen percent (14%) per annum (simple not compounded), payable in cash or shares. The Debentures will be subject to earlier redemption by the Company in the event the Common Shares are trading on the facilities of the Neo Exchange Inc. (or such other stock exchange on which the Common Shares may then be trading) at a volume weighted average trading price at or above $0.40 per share for a period of not less than ten (10) consecutive trading days.
Follow this link:
Medcolcanna Organics Inc. Announces Closing of Upsized Convertible Debenture Financing
The Company has Now Resumed the Clinical Development of its Proposed Anti-Nausea Pharmaceutical Grade Version of Tauri-Gum™
Continued here:
Tauriga Sciences Inc. Funds the Entirety of the Master Services Agreement that it Recently Entered Into with CSTI
Pompano Beach, Fl, Dec. 24, 2020 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) ("BioStem" or the "Company"), a leading life sciences company specializing in perinatal tissue allografts for use in regenerative therapies, today announced that it has filed its quarterly reports for 2020 to become current with OTC Markets.
The rest is here:
BioStem Technologies, Announces Filing of 2020 Quarterly Reports
HALIFAX, Nova Scotia, Dec. 24, 2020 (GLOBE NEWSWIRE) -- MedMira Inc. (MedMira) (TSXV: MIR), reported today on its financial results for the quarter ended October 31, 2020.
Read more here:
MedMira Reports First Quarter Results FY2021
